Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.78 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.68 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.68 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.68 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.68 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.68 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.68 |
| ▸ | NAMPT | P43490 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | KDM1A | O60341 | 1/20 | 0.62 |
| ▸ | F3 | P13726 | 1/20 | 0.62 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31720922 | 1.00 | HDAC1 (0.78) | HDAC1HDAC3HDAC2HDAC11HDAC8 | |
| SCHEMBL22798202 | 0.89 | HDAC1 (0.70) | HDAC1HDAC3HDAC2HDAC11HDAC8 | |
| SCHEMBL3646820 | 0.88 | HDAC1 (1.00) | HDAC1HDAC3HDAC2 | |
| SCHEMBL2411973 | 0.88 | HDAC1 (0.69) | HDAC1HDAC3HDAC2HDAC11HDAC8 | |
| SCHEMBL4260272 | 0.87 | HDAC1 (0.62) | HDAC1HDAC3HDAC2HDAC11HDAC8 | |
| SCHEMBL3773490 | 0.86 | HDAC1 (0.93) | HDAC1HDAC3HDAC2 | |
| SCHEMBL3948489 | 0.84 | HDAC1 (0.65) | HDAC1HDAC3HDAC2HDAC11HDAC8 | |
| SCHEMBL4254167 | 0.84 | HDAC1 (0.72) | HDAC1HDAC3HDAC2HDAC11HDAC8 | |
| SCHEMBL13949683 | 0.84 | HDAC1 (0.72) | HDAC1HDAC3HDAC2HDAC11HDAC8 | |
| SCHEMBL4463540 | 0.83 | HDAC1 (0.66) | HDAC1HDAC3HDAC2HDAC11HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3062784-B1 | ANTIMICROBIAL COMPOUNDS | AKTHELIA PHARMACEUTICALS (IS) | 2020-12-23 | — | — | EP | claimed |
| EP-2170330-A1 | SYNERGISTIC COMBINATION OF ANTHRANILAMIDE PYRIDINUREAS AND BENZAMIDE DERIVATIVES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-07 | — | — | EP | claimed |
| CN-101686970-A | Synergistic combination of anthranilamide pyridinureas and benzamide derivatives | BAYER SCHERING PHARMA AG | 2010-03-31 | — | — | CN | claimed |
| US-20090048292-A1 | SYNERGISTIC COMBINATION | BAYER SCHERING PHARMA AG (DE) | 2009-02-19 | — | — | US | claimed |
| EP-2008658-A1 | Synergistic combination of anthranilamide pyridinureas and benzamide derivatives | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-12-31 | — | — | EP | claimed |
| WO-2009000558-A1 | SYNERGISTIC COMBINATION OF ANTHRANILAMIDE PYRIDINUREAS AND BENZAMIDE DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-31 | — | — | WO | claimed |
| EP-1738752-A1 | Pharmaceutical combinations comprising cis-retine acid | Schering Aktiengesellschaft (DE) | 2007-01-03 | — | — | EP | claimed |
| EP-1641458-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-04-05 | — | — | EP | claimed |
| US-20050054647-A1 | New pharmaceutical combination | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-03-10 | — | — | US | claimed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | claimed |
| EP-3377068-B1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES INC (TW) | 2025-03-26 | — | — | EP | disclosed |
| CN-111867623-B | TOLL-like receptor ligands | 英尼穆内公司 | 2024-06-04 | — | — | CN | disclosed |
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-06-07 | — | — | US | disclosed |
| US-20220088029-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES INC (TW) | 2022-03-24 | — | — | US | disclosed |
| US-11229654-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | SENHWA BIOSCIENCES, INC. (TW) | 2022-01-25 | — | — | US | disclosed |
| EP-2008658-A1 | Synergistic combination of anthranilamide pyridinureas and benzamide derivatives | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-12-31 | — | — | EP | disclosed |
| EP-1738752-A1 | Pharmaceutical combinations comprising cis-retine acid | Schering Aktiengesellschaft (DE) | 2007-01-03 | — | — | EP | disclosed |
| EP-1641458-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-04-05 | — | — | EP | disclosed |
| US-20050054647-A1 | New pharmaceutical combination | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-03-10 | — | — | US | disclosed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054647-A1 | New pharmaceutical combination | VEGFA, INHA, PGF | HDAC1 976/4885HDAC3 1616/4885HDAC2 1101/4885 |
| US-20220088029-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | CXCR4, CXCR6, TLR7 | HDAC1 366/4885HDAC3 220/4885HDAC2 1198/4885 |
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | CDK4, CDK6, CDK2 | HDAC1 885/4885HDAC3 981/4885HDAC2 954/4885 |
| US-11229654-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | CXCR4, CXCR6, TLR7 | HDAC1 366/4885HDAC3 220/4885HDAC2 1198/4885 |
| US-20090048292-A1 | SYNERGISTIC COMBINATION | HDAC1, HDAC2, HDAC11 | HDAC1 1/4885HDAC3 4/4885HDAC2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.